See also this year's filing and all EDGAR filings for this company.
PDF Report 0001133416_2013_Galectin_Therapeutics_INC.pdf
Logs
| warning | No LiabilitiesAndStockholdersEquity node found | input.sec.calculation_linkbase.edgar_model_mapping | {'lase_node': None, 'equity_node': None, 'partners_cap_node': None, 'nodes': "NodeView(('AssetsCurrent', 'Assets', 'PropertyPlantAndEquipmentNet', 'RestrictedCashAndCashEquivalentsNoncurrent', 'IntangibleAssetsNetExcludingGoodwill', 'CashAndCashEquivalentsAtCarryingValue', 'PrepaidExpenseAndOtherAssetsCurrent', 'LiabilitiesCurrent', 'Liabilities', 'OtherLiabilitiesNoncurrent', 'AccountsPayableCurrent', 'AccruedLiabilitiesCurrent', 'DividendsPayableCurrent', 'DeferredRevenueCurrent', 'UndesignatedCapitalStockValue', 'StockholdersEquity', 'PreferredStockValue', 'CommonStockValue', 'AdditionalPaidInCapital', 'DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage'))"} |
Graph
Absolute values for 0001133416, Galectin Therapeutics INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 9,517,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 30,000 |
| 2 | PropertyPlantAndEquipmentNet | 8,000 |
| 3 | remainder_Assets | 6,000 |
| 4 | LiabilitiesCurrent | 1,638,000 |
| 5 | LiabilitiesNoncurrent | 6,000 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 5,372,000 |
| 9 | ResearchAndDevelopmentExpense | 4,527,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 224,000 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 9,561,000 |
| 1 | Liabilities | 1,644,000 |
| 2 | Expenses | 9,899,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 7,917,000 |
| 5 | NetIncome | -9,675,000 |
| 6 | ComprehensiveNetIncome | -9,675,000 |
| 7 | BaseVar | 10,664,000 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 1.35 |
| 9 | EconomicCapitalRatio | 2.57 |
Edgar->Model Mapping
Feature Distribution
Change over Time
